Trials / Completed
CompletedNCT04144842
Phase 1 Study in Patients With Advanced Solid Malignancies to Evaluate the Safety of ATOR-1017
A First-in-human, Multicenter, Open-label, Phase 1 Study in Patients With Advanced Solid Malignancies to Evaluate the Safety of Intravenously Administered ATOR-1017
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 27 (actual)
- Sponsor
- Alligator Bioscience AB · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The aim of the study is to assess the safety and tolerability of increasing doses of ATOR-1017 when administered as repeated intravenous infusions to patients with advanced and/or refractory solid malignancies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | ATOR-1017 | ATOR-1017 is a human monoclonal antibody targeting 4-1BB (CD137) |
Timeline
- Start date
- 2019-12-03
- Primary completion
- 2023-03-29
- Completion
- 2023-03-29
- First posted
- 2019-10-30
- Last updated
- 2023-04-24
Locations
3 sites across 1 country: Sweden
Source: ClinicalTrials.gov record NCT04144842. Inclusion in this directory is not an endorsement.